Result of AGM

RNS Number:5199A
VASTox plc
19 July 2007


                                   VASTox plc
                          ("VASTox" or "the Company")

                       Results of Annual General Meeting


Oxford, UK, 19 July 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, announces that at today's Annual General Meeting all resolutions,
including two special resolutions, were passed.


  * The Company will change its name from VASTox plc to Summit Corporation plc
    ("Summit plc") and with effect from the 20 of July 2007, the Company's new
    trading ticker on AIM will be "SUMM".


  * The Board has been granted authority to issue for new shares up to a
    nominal value of #1,000,000.


  * The following Directors were all re-elected to the Board of Directors: Sir
    Brian Richards, James Taylor, Barry Price, Colin Wall, Andrew Richards,
    George Elliott, Stephen Davies and David Norwood.


  * The Reports of the Directors and Auditors and the Accounts for the year
    ended 31 January 2007 were approved.  BDO Stoy Hayward LLP was also
    reappointed as the Auditors of the Company.


                                    - ends -


For more information please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer            Tel: [phone]

Darren Millington, ACMA, Chief Financial Officer


Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray        Tel: [phone]


Evolution Securities

Tim Worlledge / Bobbie Hilliam / Neil Elliot        Tel: [phone]


About VASTox plc



VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.



VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.


VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.


The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX


Further information about the company is available at www.vastox.com


This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.


Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RAGSFUFSUSWSEIW